Fireside Chat on the Current Treatment of Acute Suicidal Ideation and Behavior and Discussion on The Market Potential for Seelos Therapeutics’ SLS-002 Program
About The Event
The fireside chat will feature Evan P. Cohen, MD (Montefiore St. Luke’s Cornwall in Newburgh, New York) and John Misdary, MD (Excelis Medical Associates in Tampa, FL), who will discuss the stresses and associated healthcare costs psychiatric patients place on Emergency Departments’ physicians and staff, specifically patients with Acute Suicidal Ideation and Behavior (ASIB).
The discussion will be moderated by Michael Cozart, Managing Partner at LifeSci Consulting.
ASIB in Major Depressive Disorder (MDD) has no current FDA approved therapy and Seelos Therapeutics (Nasdaq:SEEL), seeks to address this unmet need with their investigational treatment SLS-002, intranasal racemic ketamine.
A live question and answer session will follow the discussion.